# What a 2026 GHRP-2 study measured in the adrenal system

- Article ID: research-128
- Product: GHRP-2 (ghrp-2-437)
- Canonical page: https://heritagebiolabs.com/research-library/articles/128-what-a-2026-ghrp-2-study-measured-in-the-adrenal-system
- Product collection: https://heritagebiolabs.com/research-library/products/ghrp-2
- Product page: https://heritagebiolabs.com/product/ghrp-2-437
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2025, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids joined by peptide bonds, and some act as experimental signals for glands. Growth hormone–releasing peptide 2, or GHRP-2, is a synthetic six-residue agonist of the ghrelin receptor. It is also called pralmorelin. A September 2026 study asked whether the cortisol response to a GHRP-2 challenge could help identify where a problem in the adrenal signaling pathway began. [1, 2]

The researchers looked back at records for 69 patients who had received both a corticotropin-releasing hormone (CRH) test and an insulin tolerance test. Forty-three met the study's definition of secondary adrenal insufficiency, in which the brain or pituitary supplies inadequate signals to the adrenal glands. The study classified patients further by how much cortisol they produced in response to CRH. Some people with a hypothalamic problem could still mount a cortisol response to that particular signal. [1]

Within a subgroup that responded to CRH, a low peak cortisol after the GHRP-2 challenge was specific to the hypothalamic form in this dataset. Specificity describes how well a result avoids appearing in people outside the targeted diagnostic group. It does not tell how many people with the condition the test will detect, and an estimate from a subgroup can be less precise than one from a larger cohort. The way the groups were defined also affects how the finding should be interpreted. [1]

Japan's approved pralmorelin product is labeled for diagnosing impaired growth hormone secretion. The 2026 paper studied a different outcome, cortisol, and used the compound to explore a different diagnostic question. Its retrospective design supports further validation of the result in other patients. It does not establish a new approved indication or show that GHRP-2 treats adrenal insufficiency. [1, 2]

## Sources

1. Okada N et al. Differentiating hypothalamic from pituitary adrenal insufficiency: underlying causes and diagnostic utility of the corticotropin-releasing hormone and growth hormone-releasing peptide-2 stimulation tests. Endocrine Journal (publication 2026-09-11). <https://pubmed.ncbi.nlm.nih.gov/42732957/>
2. Japan Pharmaceuticals and Medical Devices Agency. 注射用GHRP科研100. PMDA package insert (publication 2025-07). <https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/200022_7223407D2023_1_01>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 026 - GHK-Cu and GHRP-2.docx; article 128; content SHA-256 ba68a9676553cbdadc1d3016c814143a0d8190dbf1c6c4b40b9ba54c836fb92d.
